Business, energy, technology, markets and global industry news from Business News Today

classic CAH

PharmaDeviceNews classic CAH
Representative image of an endocrinology researcher reviewing adrenal hormone data, as Neurocrine Biosciences’ Crenessity update at ENDO 2026 raises new questions about treatment options for classic congenital adrenal hyperplasia.
Pharma & Biotech

Could Crenessity move beyond 21-hydroxylase CAH after Neurocrine’s ENDO 2026 data?

Find out how Neurocrine’s Crenessity data could expand rare CAH treatment thinking while key clinical questions remain.

Read More
Crenessity two-year data highlight growing interest in long-term congenital adrenal hyperplasia treatment, steroid reduction, and endocrine outcomes. Representative image.
Pharma & Biotech

Neurocrine builds long-term case for Crenessity in congenital adrenal hyperplasia

See how Neurocrine’s two-year Crenessity data may reshape long-term classic CAH care, steroid reduction and pediatric outcomes.

Read More